| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-10-14 | Myokardia (USA - CA) | nomination |
Cardiovascular diseases | Nomination | ||
| 2015-10-14 | Memorial Sloan Kettering Cancer (USA - NY) Y-mAbs Therapeutics (USA - NY) | two clinical stage fully humanized antibody programs and protein multimerization platform, MULTI-TAG™ | licensing commercialisation |
Cancer - Oncology | Licensing agreement | |
| 2015-10-13 | Protalix BioTherapeutics (Israel) Pfizer (USA - NY) | Elelyso™ (taliglucerase alfa) | Gaucher disease | development clinical research commercialisation |
Rare diseases | Development agreement |
| 2015-10-13 | Eli Lilly (USA - IN) ImaginAb (USA - CA) | T-cell-based immuno-oncology therapies | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-10-13 | Merck KGaA (Germany) | nomination |
Nomination | |||
| 2015-10-13 | Audentes Therapeutics (USA - CA) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2015-10-13 | ImaginAb (USA - CA) JFE Engineering (Japan) | 89Zr-Df-IAB2M | detection of soft tissue and bone lesions in men with high risk prostate cancer | commercialisation distribution |
Cancer - Oncology - Diagnostic | Commercialisation agreement |
| 2015-10-13 | RegenXBio (USA - MD) Dimension Therapeutics (USA - MA) | NAV vector technology | hemophilia, ornithine transcarbamylase deficiency (OTC), glycogen storage disease type 1a (GSD1a) | licensing collaboration |
Rare diseases - Genetic diseases - Hematological diseases - Metabolic diseases | Licensing agreement |
| 2015-10-13 | Asterias Biotherapeutics (USA - CA) Cell Therapy Catapult (UK) | AST-VAC2 | development establishment of a new subsidiary in the EU |
Technology - Services | Development agreement | |
| 2015-10-13 | BioSolveIT (UK) Optibrium (Germany) | integrated data analysis, visualisation and simulation software for drug research | collaboration | Technology - Services | Collaboration agreement | |
| 2015-10-13 | AOP Orphan Pharmaceuticals (Austria) | nomination |
Rare diseases | Nomination | ||
| 2015-10-13 | Sucampo Pharmaceuticals 5USA - M) | nomination |
Nomination | |||
| 2015-10-13 | Vedanta Biosciences (USA - MA) | nomination |
Autoimmune diseases – Inflammatory diseases - Infectious diseases | Nomination | ||
| 2015-10-12 | Vernalis (UK) Tris Pharma (USA - NJ) | up to six unique extended release equivalents to existing immediate release prescription cough cold treatments | cough | development |
Respiratory diseases | Development agreement |
| 2015-10-12 | Fate Therapeutics (USA - CA) | nomination |
Cancer - Oncology - Immunological diseases | Nomination | ||
| 2015-10-11 | Eli Lilly (USA - IN) Innovent Biologics (China) | cMet monoclonal antibody, monoclonal antibody targeting protein CD-20, pre-clinical immuno-oncology molecule, three anti-PD-1 based bispecific antibodies | non-small cell lung cancer, hematologic malignancies | development commercialisation |
Cancer - Oncology | Development agreement |
| 2015-10-10 | Redhill Biopharma (Israel) | resignation |
Resignation | |||
| 2015-10-10 | Eli Lilly (USA - IN) WuXi PharmaTech (Cayman), a subsidiary of Wuxi Apptec (China) | undisclosed novel small molecule addressing cardiovascular risk in patients with dyslipidemia | cardiovascular risk in patients with dyslipidemia | development manufacturing production commercialisation |
Cardiovascular diseases | Development agreement |
| 2015-10-09 | Boehringer Ingelheim (Germany) Zealand Pharma (Denmark) | therapeutic peptide project | cardiometabolic diseases | licensing |
Cardiovascular diseases - Metabolic diseases | Milestone |
| 2015-10-08 | Glycotope (Germany) Octapharma (Switzerland) | human blood coagulation factors | hemophilia | licensing |
Rare diseases - Genetic diseases - Hematological diseases | Licensing agreement |
